Impact of albumin on drug delivery--new applications on the horizon.

By Bakheet E. M. Elsadek, Felix Kratz. Journal of Controlled Release, 2012

757 citations recorded by the source corpus.

Subfields: Genetics, Oncology, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/7586e64b516386ece5cf119433608078f94c3749

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Radiology, Nuclear Medicine and Imaging

1. L. Knudsen
2. K. Howard
3. M. Kuhlmann
4. J. Lau
5. M. L. Hvam
6. M. Larsen

Citations in the corpus

• Neutralization of Human Interleukin 23 by Multivalent Nanobodies Explained by the Structure of Cytokine–Nanobody Complex (2017, background): “As a result, we were able to rationalize the construction of multivalent nanobodies, whereby the two anti-p19 nanobodies were linked to improve potency and hooked up to an antihuman serum albumin (HSA) nanobody to increase the exposure time (12).”
• The Discovery and Development of Liraglutide and Semaglutide (2019, background): “The first human-based GLP-1RA to be evaluated in clinical trials for OW dosing was taspoglutide (BIM-51077, Aib8,35 GLP-1 [7-36] amide, Roche).”
• Albumin-based drug delivery: harnessing nature to cure disease (2016, background): “Victoza® Diabetes type 2 GLP-1 Marketed Novo Nordisk [123]”